Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

A t(8;9)(p22;p24)/PCM1-JAK2 Translocation in a Patient With Myeloproliferative Neoplasm and Myeloid Sarcoma: First Report in Korea

  • Song, Ilgeun (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Dong-hyun (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Je-Hwan (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jang, Seongsoo (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Huh, Joo-Ryung (Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Seo, Eul-Ju (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2015.07.07
  • Accepted : 2015.10.01
  • Published : 2016.01.01
⟨ Previous Next ⟩

Abstract

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Bain BJ and Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 2014;166:809-17. https://doi.org/10.1111/bjh.12963
  2. Patterer V, Schnittger S, Kern W, Haferlach T, Haferlach C. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol 2013;92:759-69. https://doi.org/10.1007/s00277-013-1695-3
  3. Saba N and Safah H. A myeloproliferative neoplasm with translocation t(8;9)(p22;p24) involving JAK2 gene. Blood 2013;122:861. https://doi.org/10.1182/blood-2013-03-487348
  4. Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005;24: 7248-52. https://doi.org/10.1038/sj.onc.1208850
  5. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005;65:2662-7. https://doi.org/10.1158/0008-5472.CAN-04-4263
  6. Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol 2015;94:233-8. https://doi.org/10.1007/s00277-014-2221-y
  7. Hoeller S, Walz C, Reiter A, Dirnhofer S, Tzankov A. PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms. Expert Opin Ther Targets 2011;15: 53-62. https://doi.org/10.1517/14728222.2011.538683
  8. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 2007;21:340-50. https://doi.org/10.1038/sj.leu.2404491

Cited by

  1. PCM1 - JAK2 Fusion in a Patient With Acute Myeloid Leukemia vol.38, pp.5, 2018, https://doi.org/10.3343/alm.2018.38.5.492
  2. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes vol.95, pp.7, 2016, https://doi.org/10.1002/ajh.25825
  3. Systematic review about etiologic association to the leukoerythroblastic reaction vol.42, pp.5, 2016, https://doi.org/10.1111/ijlh.13238
  4. Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review vol.11, pp.None, 2021, https://doi.org/10.3389/fonc.2021.753842